Infliximab is a chimeric anti-TNF monoclonal antibody approved for the treatment of Crohn's disease. It is also approved for the treatment of other autoimmune diseases such as psoriasis, rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and others. It is marketed under the trade name remicade. It is developed by Jansen Biotech (Johnson & Johnson) operating as Centocor and was approved by the United States Food Drug Administration (FDA) in 1998 and by the European Medicines Agency in 1999. It was initially approved for the treatment of Crohn's disease, but since 2011 it has been approved for various indications, including rheumatoid arthritis. The patent for infliximab expired in Europe in February 2015 and will expire in the United States in September 2018. Biosimilars are defined as biotherapeutic products with similar safety and effectiveness to an approved biologic. Pfizer's Hospira subsidiary, in partnership with Celltrion, launched the first biosimilar of infliximab, namely Inflectra, in the United States in April 2016 and in Europe in June 2013. The entry of the biosimilar into the market thus stimulated the growth of the infliximab biosimilars market. In addition to this, increasing incidence and prevalence of autoimmune diseases, emergence of new participants, increasing accessibility of infliximab and price erosion have boosted the growth of the biosimilars market of infliximab. However, the strict regulatory process for approving biosimilars is hampering the market growth. Additionally, the complex nature of the molecule, extending patent terms, unavailability of FDA certified manufacturing facilities, and low tendency to switch from brand to biosimilar are hampering the growth of the biosimilar market. of infliximab. On the basis of application, the infliximab biosimilars market is segmented into Crohn's disease, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, ankylosing spondylitis, plaque psoriasis and others. Say no to plagiarism. Get a tailor-made essay on “Why Violent Video Games Should Not Be Banned”? Get the original essay The Crohn's disease followed by rheumatoid arthritis segment is expected to grow at a rapid rate during the forecast period due to increasing incidence and prevalence rate. It is estimated that 1 to 10 cases in 100,000 people have Crohn's disease. In terms of end user, the global infliximab market is segmented into hospital pharmacy, retail pharmacy and online pharmacy. The online pharmacy segment is expected to grow at a faster rate due to increasing number of internet usage, availability of various options for the buyer with attractive offers and ease of use. Regionally, the global infliximab market is segmented into North America and Europe. , Asia-Pacific, Latin America, Middle East and Africa. Europe dominates the infliximab biosimilar market, due to less stringent regulatory requirements, early entry of infliximab biosimilar into the European market (infliximab biosimilar has been available in Europe since 2013 ), the early loss of patent exclusivity and the entry of new participants. In addition to this, the increasing incidence and prevalence of chronic diseases and increasing geriatric population have boosted the market growth in Europe. North America holds the second position in the global infliximab biosimilars market due to its strong infliximab biosimilars pipeline, increasing..